Taysha Gene Therapies, Inc.TSHANASDAQ
Loading
Operating Expenses Over TimeExpanding
Percentile Rank67
3Y CAGR-1.9%
5Y CAGR+22.6%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
-1.9%/yr
Annual compound
5Y CAGR
+22.6%/yr
Recent deceleration
Percentile
P67
Within normal range
vs 5Y Ago
2.8x
Strong expansion
Streak
2 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $119.13M | +19.4% |
| 2024 | $99.79M | +13.5% |
| 2023 | $87.89M | -30.3% |
| 2022 | $126.04M | -27.3% |
| 2021 | $173.27M | +303.0% |
| 2020 | $42.99M | +3755.9% |
| 2019 | $1.11M | - |